DrugPatentWatch Database Preview
LAMPIT Drug Patent Profile
Email this page to a colleague
When do Lampit patents expire, and when can generic versions of Lampit launch?
Lampit is a drug marketed by Bayer Healthcare and is included in one NDA.
The generic ingredient in LAMPIT is nifurtimox. One supplier is listed for this compound. Additional details are available on the nifurtimox profile page.
Summary for LAMPIT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 23 |
| Clinical Trials: | 3 |
| Patent Applications: | 8 |
| Drug Prices: | Drug price information for LAMPIT |
| What excipients (inactive ingredients) are in LAMPIT? | LAMPIT excipients list |
| DailyMed Link: | LAMPIT at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for LAMPIT
Generic Entry Date for LAMPIT*:
Constraining patent/regulatory exclusivity:
INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LAMPIT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Drugs for Neglected Diseases | Phase 2 |
| U.S. Food and Drug Administration (FDA) | Phase 2 |
| Institute of Parasitology and Biomedicine Lopez Neyra | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for LAMPIT
US Patents and Regulatory Information for LAMPIT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Healthcare | LAMPIT | nifurtimox | TABLET;ORAL | 213464-001 | Aug 6, 2020 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| Bayer Healthcare | LAMPIT | nifurtimox | TABLET;ORAL | 213464-002 | Aug 6, 2020 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| Bayer Healthcare | LAMPIT | nifurtimox | TABLET;ORAL | 213464-001 | Aug 6, 2020 | RX | Yes | No | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| Bayer Healthcare | LAMPIT | nifurtimox | TABLET;ORAL | 213464-002 | Aug 6, 2020 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
